KR20140036230A - 글루코코르티코이드 수용체 매개 장애 치료용 인다졸릴 아미드 유도체의 결정질 형태 - Google Patents

글루코코르티코이드 수용체 매개 장애 치료용 인다졸릴 아미드 유도체의 결정질 형태 Download PDF

Info

Publication number
KR20140036230A
KR20140036230A KR1020137033086A KR20137033086A KR20140036230A KR 20140036230 A KR20140036230 A KR 20140036230A KR 1020137033086 A KR1020137033086 A KR 1020137033086A KR 20137033086 A KR20137033086 A KR 20137033086A KR 20140036230 A KR20140036230 A KR 20140036230A
Authority
KR
South Korea
Prior art keywords
compound
mol
mammal
solvent
crystalline
Prior art date
Application number
KR1020137033086A
Other languages
English (en)
Korean (ko)
Inventor
헬레나 잉에모 안데르손
켈리 이본느 콘웨이
마이클 존 퀘일
Original Assignee
아스트라제네카 아베
바이엘 인텔렉쳐 프로퍼티 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베, 바이엘 인텔렉쳐 프로퍼티 게엠베하 filed Critical 아스트라제네카 아베
Publication of KR20140036230A publication Critical patent/KR20140036230A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137033086A 2011-06-29 2012-06-27 글루코코르티코이드 수용체 매개 장애 치료용 인다졸릴 아미드 유도체의 결정질 형태 KR20140036230A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
US61/502,656 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
KR20140036230A true KR20140036230A (ko) 2014-03-25

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033086A KR20140036230A (ko) 2011-06-29 2012-06-27 글루코코르티코이드 수용체 매개 장애 치료용 인다졸릴 아미드 유도체의 결정질 형태

Country Status (16)

Country Link
EP (1) EP2726464A1 (es)
JP (1) JP2014527955A (es)
KR (1) KR20140036230A (es)
CN (1) CN103814015A (es)
AR (1) AR086818A1 (es)
AU (1) AU2012277514A1 (es)
BR (1) BR112013031759A2 (es)
CA (1) CA2839398A1 (es)
IN (1) IN2014MN00023A (es)
MX (1) MX2013014566A (es)
RU (1) RU2013153466A (es)
SG (1) SG195309A1 (es)
TW (1) TW201305115A (es)
UY (1) UY34170A (es)
WO (1) WO2013001294A1 (es)
ZA (1) ZA201309480B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
WO2022114105A1 (ja) * 2020-11-27 2022-06-02 ミライラボバイオサイエンス株式会社 高純度βニコチンアミドモノヌクレオチド（ＮＭＮ）及びその製造方法
CN116283781A (zh) * 2022-12-16 2023-06-23 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
ES2535701T3 (es) 2010-07-21 2015-05-14 Astrazeneca Ab Inhalador
BR112013001342A2 (pt) 2010-07-21 2016-05-17 Astrazeneca Ab dispositivo

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물
WO2024167387A1 (ko) * 2023-02-08 2024-08-15 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Also Published As

Publication number Publication date
IN2014MN00023A (es) 2015-06-12
ZA201309480B (en) 2015-10-28
JP2014527955A (ja) 2014-10-23
SG195309A1 (en) 2013-12-30
CN103814015A (zh) 2014-05-21
TW201305115A (zh) 2013-02-01
MX2013014566A (es) 2014-09-25
RU2013153466A (ru) 2015-08-10
CA2839398A1 (en) 2013-01-03
WO2013001294A1 (en) 2013-01-03
BR112013031759A2 (pt) 2016-12-13
AR086818A1 (es) 2014-01-22
AU2012277514A1 (en) 2014-01-09
EP2726464A1 (en) 2014-05-07
UY34170A (es) 2013-01-31

Similar Documents

Publication Publication Date Title
EP2291369B1 (en) Benzodioxinyl substituted indazole derivatives
RU2526038C2 (ru) Тозилатная соль производного 5-пиразолил-2-пиридона, полезная в лечении copd
JP5717727B2 (ja) ２−（４−（（２−アミノ−４−メチル−６−（ペンチルアミノ）ピリミジン−５−イル）メチル）フェニル）酢酸４−（ジメチルアミノ）ブチルの二サッカリン塩、二フマル酸塩、二ｌ−ヒドロキシ−２−ナフトエ酸塩および一安息香酸塩
AU2019213211B2 (en) Compounds
KR20050047552A (ko) 베타-2 작용제로서의 인돌 유도체
KR101866706B1 (ko) 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도
EP3610875B1 (en) Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof
US20110224229A1 (en) Novel Crystalline Form
KR20140036230A (ko) 글루코코르티코이드 수용체 매개 장애 치료용 인다졸릴 아미드 유도체의 결정질 형태
TWI391391B (zh) 多晶型
CA3170664A1 (en) P2x3 modulators
JP2001525399A (ja) 選択的β３アドレナリン作動性作動薬
KR20090026217A (ko) 치환된 5-옥사졸-2-일-퀴놀린 화합물의 크시나포에이트 염
EP3394058B1 (en) N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
CN109415348B (zh) Sgr调节剂的新的物理形式
RU2731618C2 (ru) Нестероидные модуляторы глюкокортиодидных рецепторов для местной доставки лекарств
JP2009530262A (ja) クロマン誘導体
EP3650444B1 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
CA3145120A1 (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
TW201139426A (en) Salts and hydrates of 4-[(3-chlor-4-fluor-phenyl)amino]-6-(cis-4-{n-[(morph-1-olin-4-yl)carbonyl]-n-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof
EP3960742A1 (en) Crystals of alkynyl-containing compound, salt and solvate thereof, preparation method, and applications
US10364245B2 (en) Kinase inhibitors
EP3394059B1 (en) 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
JP2019510023A (ja) 結晶形態

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid